SLPI anticorps (Center)

N° du produit ABIN500774

L’anticorps Lapin Polyclonal anti-SLPI a été validé pour WB, IHC (p) et EIA. Il convient pour détecter SLPI dans des échantillons de Humain et Souris. Il y a 1 publication disponible.

Aperçu rapide pour SLPI anticorps (Center) (ABIN500774)

Antigène: SLPI (Secretory Leukocyte Peptidase Inhibitor (SLPI))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SLPI est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Détail du produit anti-SLPI anticorps

Épitope: Center

Specificité: This antibody detects Antileukoproteinase (ALP).

Réactivité croisée (Details): Species reactivity (tested):Human, mouse

Purification: Peptide affinity chromatography

Immunogène: SLPI antibody was raised against a 17 amino acid peptide from near the center of human SLPI.

Isotype: IgG

Information d'application

Indications d'application: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Références pour anticorps anti-SLPI (ABIN500774)

Sayers, Brooks, Sayers, Chertov: "Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells." dans: PLoS ONE, Vol. 9, Issue 8, pp. e104223, (2015) (PubMed).

Détails sur SLPI

Antigène: SLPI (Secretory Leukocyte Peptidase Inhibitor (SLPI))

Autre désignation: Antileukoproteinase (ALP)

Sujet: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-kB activation by inhibiting IkB degradation in the cytoplasm and competing for NF-kB binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.Synonyms: BLPI, HUSI-1, Mucus proteinase inhibitor, Protease inhibitor WAP4, SLPI, Secretory leukocyte protease inhibitor, Seminal proteinase inhibitor, WAP four-disulfide core domain protein 4, WAP4, WFDC4

ID gène: 6590

UniProt: P03973